Articles by Patricia Van Arnum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Patricia Van Arnum

Innovation in Sourcing and Procurement

The upcoming DCAT Sharp Sourcing 2013 conference addresses the challenges and opportunities in pharmaceutical sourcing and procurement.
Jun 5, 2013

The upcoming DCAT Sharp Sourcing 2013 conference addresses the challenges and opportunities in pharmaceutical sourcing and procurement.

Novartis Receives FDA Warning Letter for cGMP Violations at Austrian Plant

The company is cited for using unapproved visual-inspection methods for finished parenteral drugs and conducting inadequate visual inspections.
Jun 5, 2013

The company is cited for using unapproved visual-inspection methods for finished parenteral drugs and conducting inadequate visual inspections.

Elucidating Heterocyclic Chemistry in Pharmaceuticals

Researchers at the Scripps Research Institute advance heteorcylic chemistry trhough new reagents and reaction-tracking techniques.
Jun 2, 2013

Researchers at the Scripps Research Institute advance heteorcylic chemistry trhough new reagents and reaction-tracking techniques.

Microwave Spectroscopy for Enantiomeric Detection of Chiral Molecules

Microwave spectroscopy overcomes some of the limitations of circular dichroism and vibrational circular dichroism in analyzing enantiomers.
Jun 2, 2013

Microwave spectroscopy overcomes some of the limitations of circular dichroism and vibrational circular dichroism in analyzing enantiomers.

Small-Molecule Drug Development: Recent Study Suggests Limited Binding Sites

A recent study of computer-created and natural proteins suggests the number of sites where small-molecule drugs can bind to proteins is limited, thereby narrowing how to mitigate side effects through drug design.
Jun 2, 2013

A recent study of computer-created and natural proteins suggests the number of sites where small-molecule drugs can bind to proteins is limited, thereby narrowing how to mitigate side effects through drug design.

Industry Perspectives: Achieving Solutions for the Challenge of Poorly Water-Soluble Drugs

A multifaceted approach is needed to resolve the myriad of challenges in developing oral formulations of poorly soluble drugs.
Jun 2, 2013

A multifaceted approach is needed to resolve the myriad of challenges in developing oral formulations of poorly soluble drugs.

FDA Issues Warning Letter to Boehringer Ingelheim for cGMP Violations

Company receives notice from FDA for not fully investigating foreign particles in APIs and finished products made from its facility in Ingelheim am Rhein, Germany.
May 28, 2013

Company receives notice from FDA for not fully investigating foreign particles in APIs and finished products made from its facility in Ingelheim am Rhein, Germany.

FDA Issues Draft Guidance on Contract Manufacturing

The draft guidance describes how quality agreements can be used to delineate the responsibilities of contract manufacturers involved in the cGMP manufacture of APIs and finished drug products.
May 28, 2013

The draft guidance describes how quality agreements can be used to delineate the responsibilities of contract manufacturers involved in the cGMP manufacture of APIs and finished drug products.

The New Normal In Biotech Financing

Financing to biotech companies in North American and Europe declined in 2012 as debt funding decreased and the IPO market remained weak.
May 3, 2013

Financing to biotech companies in North American and Europe declined in 2012 as debt funding decreased and the IPO market remained weak.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here